Education
About Us
Working with TipRanks
Follow Us
Guided Therapeutics Inc (GTHP)
OTHER OTC:GTHP
Total Valuation
Guided Therapeutics has a market cap or net worth of $29.26M. The enterprise value is $21.89M.
Market Cap$29.26M
Enterprise Value$21.89M
Share Statistics
Guided Therapeutics has 83,599,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding83,599,160
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Guided Therapeutics’s return on equity (ROE) is 0.49 and return on invested capital (ROIC) is 77.22%.
Return on Equity (ROE)0.49
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)77.22%
Return on Capital Employed (ROCE)0.44
Revenue Per Employee1.75K
Profits Per Employee-604.25K
Employee Count4
Asset Turnover<0.01
Inventory Turnover<0.01
Valuation Ratios
The current PE Ratio of Guided Therapeutics is ―. Guided Therapeutics’s PEG ratio is 0.09.
PE Ratio―
PS Ratio1228.69
PB Ratio-1.76
Price to Fair Value-1.76
Price to FCF-7.69
Price to Operating Cash Flow-25.78
PEG Ratio0.09
Income Statement
In the last 12 months, Guided Therapeutics had revenue of 7.00K and earned -2.42M in profits. Earnings per share was -0.05.
Revenue7.00K
Gross Profit2.00K
Operating Income-2.11M
Pretax Income-2.42M
Net Income-2.42M
EBITDA-1.94M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -1.11M and capital expenditures -2.00K, giving a free cash flow of -1.11M billion.
Operating Cash Flow-1.11M
Free Cash Flow-1.11M
Free Cash Flow per Share-0.01
Dividends & Yields
Guided Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.73
52-Week Price Change133.33%
50-Day Moving Average0.25
200-Day Moving Average0.20
Relative Strength Index (RSI)68.59
Average Volume (3m)12.33K
Important Dates
Guided Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Guided Therapeutics as a current ratio of 0.19, with Debt / Equity ratio of 287.38%
Current Ratio0.19
Quick Ratio0.09
Debt to Market Cap0.23
Net Debt to EBITDA-0.91
Interest Coverage Ratio-5.53
Taxes
In the past 12 months, Guided Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Guided Therapeutics EV to EBITDA ratio is -5.34, with an EV/FCF ratio of -9.27.
EV to Sales1.48K
EV to EBITDA-5.34
EV to Free Cash Flow-9.27
EV to Operating Cash Flow-9.27
Balance Sheet
Guided Therapeutics has $87.00K in cash and marketable securities with $2.37M in debt, giving a net cash position of -$2.28M billion.
Cash & Marketable Securities$87.00K
Total Debt$2.37M
Net Cash-$2.28M
Net Cash Per Share-$0.03
Tangible Book Value Per Share-$0.09
Margins
Gross margin is 73.73%, with operating margin of -30114.29%, and net profit margin of -34528.57%.
Gross Margin73.73%
Operating Margin-30114.29%
Pretax Margin-34528.57%
Net Profit Margin-34528.57%
EBITDA Margin-27728.57%
EBIT Margin-29085.71%
Analyst Forecast
The average price target for Guided Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―